Indian stocks: Visit www.stage2stocks.com →

GRAIL, Inc.

Stage 2 · Advancing · week 7

As of Oct 22, 2026, GRAIL is in Stage 2, the uptrend phase, now in week 7 (since Sep 10, 2026). It closed at $127.06, 17.5% below its 52-week high and above its 200-day average, which is rising.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. More about the company

$127.06
-4.18% today
$5.7B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is GRAL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2024-06-12 → 2026-10-22
S? 41w
S2 10w
S2 21w
S1 15w
2024-06-122026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S2 4w → S3 5w → S2 10w → S3 8w → S2 21w → S3 6w → S4 7w → S1 15w → S2 6w current
Total tracked: 123 weeks across 10 stage runs.

GRAL among Diagnostics & Research10th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…10GRALStage 2 · wk 787+17.1%
vs 52W High
-17.5%
$43.03 lo$154.08 hi
17.5% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 7
1w13w26w
Week 7, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
65.6%
200 DMA: $76.72 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.62x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+17.1%
3M
+87.3%
6M
+150.9%
YTD
+43.0%
1Y
+51.8%
Scan Membership
Breakout Watch
Latest: 2025-05-29
2 appearances in last 60 days. First seen: 2025-03-31.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 7 · Vol 0.62x
2026-10-21S2
Wk 6 · Vol 0.46x
2026-10-20S2
Wk 6 · Vol 0.70x
2026-10-19S2
Wk 6 · Vol 0.53x
2026-10-16S2
Wk 6 · Vol 1.19x
2026-10-15S2
Wk 6 · Vol 0.64x
2026-10-14S2
Wk 5 · Vol 0.76x
2026-10-13S2
Wk 5 · Vol 0.65x
2026-10-12S2
Wk 5 · Vol 0.60x
2026-10-09S2
Wk 5 · Vol 0.72x
2026-10-08S2
Wk 5 · Vol 1.24x
2026-10-07S2
Wk 4 · Vol 0.94x
Moving averages & range
50 DMA
$102.90
200 DMA
$76.72
52W High
$154.08
52W Low
$43.03
5D Low
$117.81
Resistance levels (recent highs)
20d High
$154.08
60d High
$154.08
120d High
$154.08
250d High
$154.08
Next resistance
+21.3%
to 20d High
ROE
-16.1%
Profit margin -236.9%
Dividend Yield
0.00%
P/B 2.2

GRAIL: quick answers

What stage is GRAIL in?

As of Oct 22, 2026, GRAIL (GRAL) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 10, 2026 and is in week 7. What the four stages mean

Is GRAIL in an uptrend?

Yes. GRAIL is in a Stage 2 uptrend. It trades 65.6% above its 200-day average, which is rising.

How far is GRAIL from its 52-week high?

GRAIL closed at $127.06 on Oct 22, 2026, 17.5% below its 52-week high of $154.08. Its 52-week low is $43.03.

How has GRAIL performed over the past year?

As of Oct 22, 2026, GRAIL is up 51.8% over the past year and up 43.0% so far in 2026.

Which sector and industry is GRAIL in?

GRAIL is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.